Prolonged treatment with the AT1 receptor blocker, valsartan, increases small and large artery compliance in uncomplicated essential hypertension

American Journal of Hypertension

Volumn 15, Issue 12, 2002, Pages 1087-1091

  Shargorodsky, Marina ^a   Leibovitz, Eyal ^a,b   Lubimov, Leonid ^a   Gavish, Dov ^a,b   Zimlichman, Reuven ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b WOLFSON MEDICAL CENTER   (Israel)

Author keywords

Arterial compliance; AT1 antagonists; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; VALSARTAN; ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; VALINE;

ADULT; ARTERY COMPLIANCE; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; RADIAL ARTERY; RECEPTOR BLOCKING; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; WAVEFORM; DRUG ANTAGONISM; DRUG EFFECT; ELASTICITY; MIDDLE AGED; PATHOPHYSIOLOGY; VASCULAR RESISTANCE;

ANTIHYPERTENSIVE AGENTS; ELASTICITY; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; TETRAZOLES; TREATMENT OUTCOME; VALINE; VASCULAR RESISTANCE;

EID: 0036892791     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(02)03134-5     Document Type: Article

References (17)

1. National High Blood Pressure Education Program Working Group: Report on hypertension in the elderly. Hypertension 1994;23:275-285.
2. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, Ducimetiere P, Benetos A: Aortic stiffness is an independent predictor of all cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-1241.
3. SHEP Cooperative Research Group: Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991;265:3255-3264.
4. Dahlof B, Hansson L, Hindholm LH, Schersten B, Ekbom T, Wester PO: Swedish Trial in Old Patients with Hypertension (STOP-Hypertension): Analyses performed up to 1992. Clin Exp Hypertens 1993;15:925-939.
5. Cohn J: Vascular wall function as a risk marker for cardiovascular disease. J Hypertens 1999;17(Suppl 5):s41-s44.
6. Cohn JN: Pathophysiologic and prognostic implications of measuring arterial compliance in hypertensive disease. Prog Cardiovasc Dis 1999;41:441-450.
7. Cohn JN, Finkelstein S, McVeigh G, Morgan D, LeMay L, Robinson J, Mock J: Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension 1995;26:503-508.
8. Neutel JM, Smith DHG, Graettinge WF, Weber MA: Dependency of arterial compliance on circulating neuro-endocrine and metabolic factors in normal subjects. Am J Cardiol 1992;69:1340-1344.
9. Glasser SP, Arnett DK, McVeigh GE, Finkelstein SM, Bank AJ, Morgan DJ, Cohn JN: Vascular compliance and cardiovascular disease: A risk factor or a marker? Am J Hypertens 1997;10:1175-1189.
10. McVeigh GE: Effects of perindopril on cardiovascular remodeling. Am J Cardiol 2001;88(Suppl):28i-35i.
11. Simon A, Levenson J: Use of arterial compliance for evaluation of hypertension. Am J Hypertens 1991;4:97-105.
12. Liao D, Arnett DK, Tyroler HA, Riley WA, Chambless LE, Szklo M, Weiss G: Arterial stiffness and the development of hypertension. The ARIC study. Hypertension 1999;34:201-206.
13. McVeigh GE, Hamilton PK, Morgan DR: Evaluation of mechanical arterial properties: Clinical, experimental and therapeutic aspects. Clin Sci 2002;102:51-67.
14. Levy BI, Michel J-B, Salzman J-L, Devissageut M, Safar ME: Remodeling of heart and arteries by chronic converting enzyme inhibition in spontaneously hypertensive rats. Am J Hypertens 1991; 4(Suppl):240S-245S.
15. Barra JG, Levenson J, Armenato RL, Cabrera Fisher EI, Pichel RH, Simon A: In vivo angiotensin II receptor blockade and converting enzyme inhibition on canine aortic viscoelasticity. Am J Physiol 1997;27:H859-H868.
16. Nalbantgil S, Yilmaz H, Gurun C, Ozerkan F, Nalbantgil I, Onder R: Effect of valsartan and enalapril on regression of left ventricular hypertrophy in patients with mild to moderate hypertension: A randomized, double-blind study. Curr Ther Res 2000; 61:331-338.
17. Mahmud E, Feely J: Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002;15:321-325.